Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
Effects of Tirzepatide on the Clinical Trajectory of Patients with Heart Failure, a Preserved Ejection Fraction, and Obesity
Comparative Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists to Dipeptidyl Peptidase 4 Inhibitors in Patients With Heart Failure and Type 2 Diabetes
Prognostic Benefit of GLP-1 RA Addition to SGLT2i in Patients with ASCVD and Heart Failure: A Cohort Study
Glucagon-Like Peptide 1 Receptor Agonist Is Associated With Improved Survival in Overweight Heart Failure Patients
Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction
